Related posts
Inflation data and hike fears pressure stocksThis summary was created by AI, based on 3 opinions in the last 12 months.
The experts have differing views on Dexcom (DXCM-Q). Trevor Rose's Insights believes that the recent sell-off is overdone and sees value in holding the stock due to its strong financials, growing market share, and expanding footprint. However, there is a concern that the success of weight loss drugs may reduce demand for diabetes monitoring products. Another expert points out that Dexcom does well when diabetes is booming but cautions about potential impact from new drugs. The third expert regrets not selling oil holdings today. Overall, there is a mix of positive and cautionary sentiments regarding the stock.
Does well when (sadly) diabetes is booming. The fear is that drugs develop from Novo Nordisk and Eli Lilly will cut down on diabetes. He tends to agree. Be careful here.
He regrets he didn't sell some of his oil holdings today. He doesn't see the price of oil moving up from here, but will move down.
Dexcom is a American stock, trading under the symbol DXCM-Q on the NASDAQ (DXCM). It is usually referred to as NASDAQ:DXCM or DXCM-Q
In the last year, 3 stock analysts published opinions about DXCM-Q. 1 analyst recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Dexcom.
Dexcom was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Dexcom.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Dexcom In the last year. It is a trending stock that is worth watching.
On 2024-05-02, Dexcom (DXCM-Q) stock closed at a price of $126.58.
DXCM has been hit hard as investors fear new success of weight loss drugs will reduce demand for diabetes monitoring products. DXCM is not alone in the decline. But it is still growing, and recent comments by analysts suggest the sell off is quite overdone. It has new products on tap and is strong financially. Market share remains robust. Best Buy has started selling its products (not material on its own, but shows an expanding footprint). We would see DXCM as worth holding. Because it is 33X as large was WELL, they are hard to compare. WELL, being smaller, could potentially rise more, but comes with much more overall risk. From a safety and valuation standpoint, we would, today, prefer DXCM.
Unlock Premium - Try 5i Free